To make a randomized comparison of @ consolidation treatment options ( two patient groups ) : @ cycles of cytarabine in average ( Ig/m@ in Group @ ) and standard ( @ mg/mi@ in Group @ ) doses in combination with idarubicin ( @-@ mg/m@ ) and mitoxantrone ( @ mg/m@ ) , after two @ +@ induction cycles of daunorubicin ( @ mg/mi@ ) and subsequent @ cycles of maintenance therapy .